Radiotherapy Department, Institut de Cancérologie Strasbourg-Europe, Strasbourg, France.
Nuclear Medicine Department, Institut de Cancérologie Strasbourg-Europe, Strasbourg, France.
Chin Clin Oncol. 2021 Jun;10(3):26. doi: 10.21037/cco-20-226. Epub 2021 Mar 10.
Atypical meningioma is a variant of meningioma with a high risk of recurrence. Gross total resection is the standard of treatment, while no consensus on optimal adjuvant management has been found.
Between 2008 and 2018, a retrospective search identified 216 grade II meningiomas treated in six centers. Clinical, histological, and therapeutic data were analyzed to determine the prognostic factors of recurrence and survival.
In total, 216 patients underwent surgical resection. Among these, 122 patients (56%) underwent gross total resection, and 21% of the patients received adjuvant radiotherapy. Univariate analysis reported subtotal resection, high Ki-67, negative progesterone receptor (PR) and histological grade evolution as unfavorable prognosis factors. According to multivariate analysis, the Ki-67 proliferative index (cut-off value of 17.5%) was the only prognostic factor of recurrence (HR 1.1; 95% CI, 1.0-1.2, P=0.048). Gross total resection improved progression-free survival (PFS) (P=0.03) but without impact on overall survival (OS) (P=0.2). Median PFS and OS times were longer for patients receiving adjuvant radiotherapy than those who did not receive adjuvant radiotherapy. PFS (P=0.3) and OS (P=0.7) were associated with adjuvant RT by trend only. After a median follow-up time of 6.7 years, 99 (46%) patients relapsed. Median progression-free and OS rates were 4.5 (95% CI, 3.5-5.5) and 14.7 years (11.4-NA), respectively.
In this study, Ki-67 proliferative index was significantly associated with recurrence. Gross total resection significantly improved PFS without impacting OS. Adjuvant radiotherapy delayed recurrence and improved OS, but a longer follow-up time is needed to distinguish a statistically significant difference. Large prospective studies are needed to determine postoperative treatment guidelines.
非典型脑膜瘤是一种具有高复发风险的脑膜瘤变体。完全切除是标准的治疗方法,但是对于最佳辅助治疗尚未达成共识。
在 2008 年至 2018 年间,通过回顾性搜索在六个中心中确定了 216 例 II 级脑膜瘤患者。分析了临床、组织学和治疗数据,以确定复发和生存的预后因素。
共有 216 例患者接受了手术切除。其中,122 例患者(56%)行大体全切除,21%的患者接受了辅助放疗。单因素分析报告次全切除、高 Ki-67、孕激素受体(PR)阴性和组织学分级进展为不良预后因素。根据多因素分析,Ki-67 增殖指数(截值为 17.5%)是唯一的复发预后因素(HR 1.1;95%CI,1.0-1.2,P=0.048)。大体全切除可改善无进展生存期(PFS)(P=0.03),但对总生存期(OS)无影响(P=0.2)。接受辅助放疗的患者的中位 PFS 和 OS 时间长于未接受辅助放疗的患者。PFS(P=0.3)和 OS(P=0.7)仅呈趋势与辅助 RT 相关。中位随访时间为 6.7 年后,有 99 例(46%)患者复发。无进展生存期和 OS 率的中位数分别为 4.5 年(95%CI,3.5-5.5)和 14.7 年(11.4-NR)。
在这项研究中,Ki-67 增殖指数与复发显著相关。完全切除显著改善了 PFS,而对 OS 无影响。辅助放疗延迟了复发并改善了 OS,但需要更长的随访时间才能区分出统计学上的显著差异。需要进行大型前瞻性研究来确定术后治疗指南。